Drug-approval veteran Rajiv Patni joins Septerna (Nasdaq: SEPN) as CMO
Rhea-AI Filing Summary
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, announced the appointment of Rajiv Patni, M.D. as Chief Medical Officer, effective August 24, 2026. The appointment was communicated via an August 25, 2026 press release furnished as an exhibit.
Dr. Patni is a physician-scientist and biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory and medical affairs organizations. He previously held senior roles including Chief Executive Officer of Judo Bio and Chief Research and Development Officer at Reata Pharmaceuticals, as well as Chief Medical Officer positions at several other biopharma companies.
Septerna highlights Dr. Patni’s track record contributing to programs that led to 10 regulatory agency approvals or label expansions across the United States, Europe and additional markets. The company describes itself as advancing a pipeline of novel oral small molecule drug candidates using its proprietary Native Complex Platform® in endocrinology, immunology, inflammation, metabolic diseases and other therapeutic areas.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
G protein-coupled receptor (GPCR) medical
clinical-stage biotechnology company financial
Native Complex Platform® technical
regulatory agency approvals regulatory
FAQ
What did Septerna, Inc. (SEPN) announce regarding its leadership team?
Who is the new Chief Medical Officer of Septerna (SEPN) and what is his background?
What experience does Septerna’s (SEPN) new CMO bring in terms of drug approvals?
When did Septerna’s (SEPN) Board appoint Rajiv Patni, M.D. as Chief Medical Officer?
What therapeutic areas does Septerna (SEPN) target with its GPCR-focused pipeline?
How does Septerna (SEPN) describe its stage and scientific focus?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure. |
On August 25, 2026, Septerna, Inc. (the “Company”) issued a press release entitled “Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished under this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 8.01 | Other Information. |
Effective August 24, 2026, the Company’s Board of Directors appointed Rajiv Patni, M.D., as the Company’s Chief Medical Officer.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | Press Release issued by Septerna, Inc. on August 25, 2026, furnished herewith. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Septerna, Inc. | ||||||
| Date: August 25, 2026 | By: | /s/ Jeffrey Finer, M.D., Ph.D. | ||||
| Jeffrey Finer, M.D., Ph.D. Chief Executive Officer | ||||||
Exhibit 99.1
|
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. – August 25, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.
“We are thrilled to welcome Rajiv to the team as we execute on our strategy to develop differentiated oral medicines targeting GPCRs,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. “Rajiv brings deep clinical development experience across multiple therapeutic areas and a successful track record of guiding investigational medicines from early clinical studies through regulatory agency approvals. His leadership will be instrumental as we advance our clinical programs and continue to build a world-class development organization to deliver new medicines for patients in need.”
“Throughout my career I have joined companies at inflection points in their R&D trajectory, and that is where Septerna is today,” said Dr. Patni. “Our pipeline targets significant unmet needs spanning endocrinology, immunology, and other therapeutic areas. I look forward to helping translate Septerna’s unique expertise in GPCR drug discovery into clinical evidence and ultimately into important new medicines for patients who need better oral treatment options.”
Dr. Patni joins Septerna from Judo Bio where he most recently served as Chief Executive Officer. Previously, he was Chief Research and Development Officer at Reata Pharmaceuticals. Earlier, Dr. Patni served as Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, Adamas Pharmaceuticals and Actelion Pharmaceuticals, companies that, together with Reata, were subsequently acquired. Earlier in his career, Dr. Patni led development teams at Pfizer and Roche Pharmaceuticals. Over the course of his career, Dr. Patni has contributed to programs that resulted in 10 regulatory agency approvals or label expansions in the United States, Europe and additional markets. He currently serves as a director of BioXcel Therapeutics.
Dr. Patni holds an M.D. from the Icahn School of Medicine at Mt. Sinai and completed his internal medicine residency and cardiology fellowship at the Albert Einstein College of Medicine.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com